Lassen Therapeutics announced positive new preclinical data on LASN01, their novel IL-11 receptor-blocking antibody intended to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). The data were presented at the American Thoracic Society Annual Meeting in San Francisco, California on May 17, 2022.
“IL-11 is a key biological mediator in many fibrotic diseases including [IPF],” David King, PhD, chief scientific officer of Lassen, said. “We are presenting data on the ability of LASN01 to block signaling through the [IL-11 receptor] leading to clear effects on fibrotic biomarkers in human tissue, as well as reducing lung fibrosis in preclinical tissue models.”
“Combined, these data strongly indicate the potential of LASN01 as a novel therapeutic approach for treatment of IPF and other fibrosing interstitial lung diseases.”
Read more about IPF therapies
LASN01 is a potent IL-11 signaling inhibitor, and inhibition of the IL-11 receptor has been shown to have an antifibrotic effect in various preclinical and animal models of fibrosis. In addition to the blockade of IL-11 stimulated signaling, LASN01 also led to inhibition of TGF-β-stimulated collagen expression by IPF fibroblasts from patients.
Prophylactic and therapeutic studies have also shown a significant reduction in lung fibrosis, along with a reduction in the macrophage populations. Moreover, in primate studies, LASN01 was well tolerated and had no notable toxicity. The company expects LASN01 to rapidly advance toward clinical evaluation.
Lassen Therapeutics presents data demonstrating preclinical anti-fibrotic effect of LASN01, a novel IL-11 receptor-blocking antibody, at the American Thoracic Society 2022 Annual Meeting. News release. Lassen Therapeutics; May 17, 2022.